Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1385-1388

  Huesgen, Emily ^a   Burgos, Rodrigo ^a   Goldstein, Debra A ^a   Max, Blake ^a,b   Jarrett, Olamide D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Department of Ambulatory and Community Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATORVASTATIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; EZETIMIBE; FELODIPINE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LOPINAVIR PLUS RITONAVIR; OMEGA 3 FATTY ACID; RALTEGRAVIR; TAMSULOSIN; TENOFOVIR DISOPROXIL; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CATARACT; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; RETINA DISEASE; RETINA LIPEMIA; SIDE EFFECT; VIREMIA;

CHOLESTEROL, HDL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; PYRROLIDINONES; RITONAVIR; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84870559767     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2182     Document Type: Article

References (20)

1. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apoC-III variants and protease inhibitors contributes to high triglycerides/low HDL levels in treated HIV patients. AIDS 2001; 15:2397-2406.
2. Martínez E, Domingo P, Galindo MJ, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavirritonavir. Clin Infect Dis 2004; 38:1017-1023.
3. Calza L, Manfredi R, Farneti B, et al. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003; 22:54-59.
4. Gutiérrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003; 33:594-600.
5. González de Requena D, Blanco F, Garcia-Benayas T, et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS 2003; 17:443-445.
6. Bierman WF, van Vonderen MG, Veldkamp AI, et al. The lopinavir/ritonavir- associated rise in lipids is not related to lopinavir or ritonavir plasma concentration. Antivir Ther 2011; 16:647-655.
7. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir- based regimen is noninferior to twicedaily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009; 50:474-481.
8. Lafeuillade A, Hittinger G, Philip G, et al. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra). HIV Clin Trials 2004; 5:392-398.
9. Murphy RL, da Silvia BA, Hicks CB, et al. Sevenyear efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2008; 9:1-10.
10. Hydrochlorothiazide. In: DRUGDEX® System. Version 5.1. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
11. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245.
12. Reynes J, Lawal A, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naive HIV-1 infected subjects. 18th International AIDS Conference. 18-23 July 2010, Vienna, Austria. Abstract MAOB01.
13. Isentress. Package insert 2007. Merck & Co., Inc, Whitehouse Station, NJ, USA.
14. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravirbased regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
15. Bedimo R, Drechsler H, Turner D, et al. RADAR study: raltegravir combined with boosted darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. 6th IAS Conference. 17-20 July 2011, Rome, Italy. Abstract MOPE214.
16. Kozal MJ, Lupo S, DeJesus E, et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300 mg BID plus raltegravir (RAL) 400 mg BID (ATV + RAL) in treatmentnaive HIV-infected subjects. 18th International AIDS Conference. 18-23 July 2010, Vienna, Austria. Abstract THLBB204.
17. Kaletra. Package insert 2000. Abbott Laboratories, North Chicago, IL, USA.
18. Huisman MT, Smit JW, Crommentuyn KM, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16:2295-2301.
19. Moss DM, Kwan WS, Liptrott NJ, et al. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2011; 55:879-887.
20. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011; 32:945-951.